Circulating concentrations of monocyte chemoattractant protein-1, plasminogen activator inhibitor-1, and soluble leukocyte adhesion molecule-1 in overweight/obese men and women consuming fructose- or glucose-sweetened beverages for 10 weeks

J Clin Endocrinol Metab. 2011 Dec;96(12):E2034-8. doi: 10.1210/jc.2011-1050. Epub 2011 Sep 28.

Abstract

Context: Results from animal studies suggest that consumption of large amounts of fructose can promote inflammation and impair fibrinolysis. Data describing the effects of fructose consumption on circulating levels of proinflammatory and prothrombotic markers in humans are unavailable.

Objective: Our objective was to determine the effects of 10 wk of dietary fructose or glucose consumption on plasma concentrations of monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), E-selectin, intercellular adhesion molecule-1, C-reactive protein, and IL-6.

Design and setting: This was a parallel-arm study with two inpatient phases (2 wk baseline, final 2 wk intervention), conducted in a clinical research facility, and an outpatient phase (8 wk) during which subjects resided at home.

Participants: Participants were older (40-72 yr), overweight/obese (body mass index = 25-35 kg/m(2)) men (n = 16) and women (n = 15).

Interventions: Participants consumed glucose- or fructose-sweetened beverages providing 25% of energy requirements for 10 wk. Blood samples were collected at baseline and during the 10th week of intervention.

Main outcome measures: Fasting concentrations of MCP-1 (P = 0.009), PAI-1 (P = 0.002), and E-selectin (P = 0.048) as well as postprandial concentrations of PAI-1 (P < 0.0001) increased in subjects consuming fructose but not in those consuming glucose. Fasting levels of C-reactive protein, IL-6, and intercellular adhesion molecule-1 were not changed in either group.

Conclusions: Consumption of fructose for 10 wk leads to increases of MCP-1, PAI-1, and E-selectin. These findings suggest the possibility that fructose may contribute to the development of the metabolic syndrome via effects on proinflammatory and prothrombotic mediators.

Trial registration: ClinicalTrials.gov NCT01165853.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Aged
  • Beverages
  • Blood Glucose / metabolism
  • C-Reactive Protein / metabolism
  • Chemokine CCL2 / blood*
  • E-Selectin / blood
  • Female
  • Fructose / administration & dosage*
  • Glucose / administration & dosage*
  • Humans
  • Intercellular Adhesion Molecule-1 / blood
  • L-Selectin / blood*
  • Male
  • Middle Aged
  • Obesity / blood*
  • Overweight / blood*
  • Plasminogen Activator Inhibitor 1 / blood*
  • Postprandial Period / drug effects
  • Postprandial Period / physiology
  • Sweetening Agents / administration & dosage

Substances

  • Blood Glucose
  • Chemokine CCL2
  • E-Selectin
  • Plasminogen Activator Inhibitor 1
  • Sweetening Agents
  • Intercellular Adhesion Molecule-1
  • L-Selectin
  • Fructose
  • C-Reactive Protein
  • Glucose

Associated data

  • ClinicalTrials.gov/NCT01165853